Informazioni cliniche
Le infezioni sessualmente trasmesse (IST) possono essere causate da batteri (ad esempio Treponema pallidum, Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma), virus (ad esempio HSV) o parassiti (Trichomonas vaginalis), che vengono trasmessi da persona a persona tramite sesso vaginale, anale o orale. Il decorso, i sintomi e le conseguenze delle IST possono variare notevolmente a seconda dell'agente patogeno causale. In molti casi l'infezione è asintomatica, per cui rimane a lungo nascosta e viene diagnosticata solo quando diventa cronica. Le infezioni da questi agenti patogeni spesso causano infiammazioni del tratto urogenitale, che possono evolvere e portare, ad esempio, all'infertilità. Alcuni agenti patogeni causano alterazioni cellulari che talvolta possono portare al cancro del collo dell'utero.
Oltre alle conseguenze per il paziente, le infezioni con la maggior parte degli agenti patogeni citati possono anche portare alla perdita intrauterina del feto, al parto pretermine o a danni al nascituro. Inoltre, molti agenti patogeni possono essere trasmessi al neonato durante il parto, causando gravi infezioni postnatali.
Diagnostica
I metodi di rilevamento comunemente utilizzati per le IST sono i metodi diretti, in cui l'agente patogeno viene rilevato mediante PCR o coltura, e i metodi indiretti, cioè il rilevamento di anticorpi specifici dell'agente patogeno. Poiché la rilevazione mediante coltura è particolarmente lunga e difficile per Chlamydia, Mycoplasma, Ureaplasma e Treponema, per questi patogeni sono generalmente raccomandati o richiesti altri metodi di rilevazione, ad esempio basati su PCR e/o procedure sierologiche.
| Technology | Parameter | Substrate | Species | Calibration | Ig Class | Format | Order No. |
|---|---|---|---|---|---|---|---|
| ELISA |
CSQ pair of controls anti-HSV-1/2 Pool (IgG) |
IgG |
02 x 20 |
CK 2531-0220-1 L G | |||
| ELISA |
CSF: Anti-HSV-1/2 Pool ELISA (IgG) herpes simplex virus Sample type: CSF/serum pair |
antigen-coated microplate wells |
native antigens from HSV-1 and HSV-2 |
5/25/50/100/175/230 U/ml | IgG |
96 x 01 |
EI 2531-9601-1 L G |
| ELISA |
CSQ pair of controls anti-Treponema pallidum (IgG) |
IgG |
02 x 20 |
CK 2111-0220-L G | |||
| ELISA |
CSF: Anti-Treponema pallidum ELISA (IgG) Sample type: CSF/serum pair |
antigen-coated microplate wells |
recombinant antigens 15 kDa, 17 kDa, 47 kDa, 42 kDa (TmpA) |
5/25/50/100 U | IgG |
96 x 01 |
EI 2111-9601-L G |
| ELISA |
Anti-HSV-1/2 Pool ELISA (IgG) herpes simplex virus native antigens from HSV-1 and HSV-2 |
antigen-coated microplate wells |
native antigens from HSV-1 and HSV-2 |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 2531-9601-1 G |
| ELISA |
Anti-HSV-1/2 Pool ELISA (IgM) herpes simplex virus native antigens from HSV-1 and HSV-2 |
antigen-coated microplate wells |
native antigens from HSV-1 and HSV-2 |
semi-quantitative | IgM |
96 x 01 |
EI 2531-9601-1 M |
| ELISA |
Anti-HSV-1 (gC1) ELISA (IgG) herpes simplex virus 1 recombinant glycoprotein C1 from HSV-1 |
antigen-coated microplate wells |
recombinant glycoprotein C1 |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 2531-9601-2 G |
| ELISA |
Anti-HSV-2 (gG2) ELISA (IgG) herpes simplex virus 2 recombinant glycoprotein G2 from HSV-2 |
antigen-coated microplate wells |
recombinant glycoprotein G2 |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 2532-9601-2 G |
| WESTERNBLOT |
antibodies against Herpes simplex virus (HSV) IgG positive control |
IgG |
50 x 05 |
CW 2531-5005 G | |||
| WESTERNBLOT |
Anti-HSV-1 / HSV-2 gG-2 EUROLINE-WB (IgG) Herpes simplex virus 1 (HSV-1) plus HSV-2 type-specific glycoprotein G2 |
Westernblot |
whole antigen, SDS extract of HSV-1 plus purified gG2 |
IgG |
16 x 01 |
DY 2531-1601-1 G | |
| WESTERNBLOT |
Anti-HSV-1 / HSV-2 gG-2 EUROLINE-WB (IgM) Herpes simplex virus 1 (HSV-1) plus HSV-2 type-specific glycoprotein G2 |
Westernblot |
whole antigen, SDS extract of HSV-1 plus purified gG2 |
IgM |
16 x 01 |
DY 2531-1601-1 M | |
| ChLIA | IDS HSV-1 IgG | antigenic coated magnetic particles | gG1 antigen |
quantitative |
100 x 01 |
IS-ID56011 | |
| ChLIA | IDS HSV-2 IgG | antigenic coated magnetic particles | gG2 antigen |
quantitative |
100 x 01 |
IS-ID56021 | |
| ChLIA | IDS HSV 1/2 IgG Control Set | 3 x 1.5 ml Control 1/2 | human serum |
2 concentrations |
IS-ID56301 | ||
| ChLIA | IDS HSV 1/2 IgM | antigenic coated magnetic particles | gG1 and gG2 antigens |
quantitative |
100 x 01 |
IS-ID57011 | |
| ChLIA | IDS HSV 1/2 IgM Control Set | 3 x 1.5 ml Control 1/2 | human serum |
2 concentrations |
IS-ID57301 | ||
| ChLIA | Anti-Herpes simplex virus 1 ChLIA (IgG) | Antigen-coated magnetic particles | recombinant gG1 | quantitative | IgG |
100 x 1 |
LI 2531-10010 G |
| ChLIA | Anti-Herpes simplex virus 2 ChLIA (IgG) | Antigen-coated magnetic particles | rekombinant gG2 | quantitative | IgG |
100 x 1 |
LI 2532-10010 G |
| ChLIA | Control set Anti-HSV 1 ChLIA (IgG) | 2 x 0.5 ml control 1/2 | IgG |
02 x 02 |
LR 2531-20210 G | ||
| ChLIA | Control set Anti-HSV 2 ChLIA (IgG) | 2 x 0.5 ml control 1/2 | IgG |
02 x 02 |
LR 2532-20210 G | ||
| EUROArray | EUROArray STI - 11 |
MN 2830-0505 MN 2830-0803 MN 2830-1005 MN 2830-2005 |
|||||
| EUROArray | EUROArray HPV |
MN 2540-0505 MN 2540-0803 MN 2540-1005 MN 2540-2005 |
|||||
| ELISA | Anti-Chlamydia trachomatis Advanced ELISA (IgA) | semi-quantitative | IgA |
96 x 01 |
EI 2191-9601-1 A | ||
| ELISA | Anti-Chlamydia trachomatis Advanced ELISA (IgG) | quantitative | IgG |
96 x 01 |
EI 2191-9601-1 G | ||
| IIFT |
Treponema pallidum (FTA-ABS) |
bacterial smear verification BIOCHIP (2 BIOCHIPs per field) |
T. pallidum | IgG IgM IgG IgM |
10 x 05 10 x 05 10 x 10 10 x 10 |
FI 2111-1005 G FI 2111-1005 M FI 2111-1010 G FI 2111-1010 M |
|
| IIFT |
Treponema pallidum (FTA-ABS) |
bacterial smears verification BIOCHIP (3 BIOCHIPs per field) |
T. pallidum T. phagedenis |
IgG IgM IgG IgM |
10 x 05 10 x 05 10 x 10 10 x 10 |
FI 2112-1005 G FI 2112-1005 M FI 2112-1010 G FI 2112-1010 M |
|
| IIFT |
Anti-Chlamydia MIF Chlamydia trachomatis Chlamydia pneumoniae Chlamydia psittaci |
4 BIOCHIPs per field: elementary bodies and non-infected cells |
EU 40 EU 40 EU 40 |
IgA EB IgG EB IgM EB IgA EB IgG EB IgM EB |
10 x 05 10 x 05 10 x 05 10 x 10 10 x 10 10 x 10 |
FI 2191-1005-3 A FI 2191-1005-3 G FI 2191-1005-3 M FI 2191-1010-3 A FI 2191-1010-3 G FI 2191-1010-3 M |
|
| IIFT | Chlamydia trachomatis |
elementary bodies (MIF) non-infected cells (2 BIOCHIPs per field) |
EU 40 EU 40 |
IgA EB IgG EB IgM EB |
10 x 05 10 x 05 10 x 05 |
FI 2191-1005-80 A FI 2191-1005-80 G FI 2191-1005-80 M |
|
| IIFT |
Anti-Chlamydia MIF EUROPattern Chlamydia trachomatis Chlamydia pneumoniae Chlamydia psittaci |
4 BIOCHIPs per field: elementary bodies and non-infected cells |
EU 40 EU 40 EU 40 |
IgA EB IgG EB IgM EB IgA EB IgG EB IgM EB |
10 x 05 10 x 05 10 x 05 10 x 10 10 x 10 10 x 10 |
FR 2191-1005-3 A FR 2191-1005-3 G FR 2191-1005-3 M FR 2191-1010-3 A FR 2191-1010-3 G FR 2191-1010-3 M |
|
| ELISA | Anti-Treponema pallidum ELISA (IgG) |
antigen-coated microplate wells |
recombinant antigens 15 kDa, 17 kDa, 47 kDa, 42 kDa (TmpA) |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 2111-9601 G |
| ELISA | Anti-Treponema pallidum ELISA (IgM) |
antigen-coated microplate wells |
recombinant antigens 15 kDa, 17 kDa, 47 kDa, 42 kDa (TmpA) |
semi-quantitative | IgM |
96 x 01 |
EI 2111-9601 M |
| ELISA | Anti-Treponema pallidum ELISA 2.0 (IgGM) | 200/50/20/2 RU/ml | IgGM |
96 x 01 |
EI 2111-9601-2 O | ||
| ELISA | Anti-Chlamydia trachomatis ELISA (IgA) |
antigen-coated microplate wells |
native MOMP antigen from C. trachomatis |
semi-quantitative | IgA |
96 x 01 |
EI 2191-9601 A |
| ELISA | Anti-Chlamydia trachomatis ELISA (IgG) |
antigen-coated microplate wells |
native MOMP antigen from C. trachomatis |
2/20/200 RU/ml | IgG |
96 x 01 |
EI 2191-9601 G |
| ELISA | Anti-Chlamydia trachomatis ELISA (IgM) |
antigen-coated microplate wells |
native MOMP antigen from C. trachomatis |
semi-quantitative | IgM |
96 x 01 |
EI 2191-9601 M |
| EUROLINE |
positive control serum: IgG, human, 50x concentrated for Treponema pallidum |
IgG |
05 x 07 |
CL 2111-0507 G | |||
| EUROLINE |
positive control serum: IgM, human, 50x concentrated for Treponema pallidum |
IgM |
05 x 07 |
CL 2111-0507 M | |||
| EUROLINE |
EUROLINE Anti-Treponema pallidum (IgG) (TpN15, TpN17, TmpA, TpN47 separately) |
EUROLINE | IgG IgG |
16 x 01 64 x 01 |
DN 2111-1601 G DN 2111-6401 G |
||
| EUROLINE |
EUROLINE Anti-Treponema pallidum (IgM) (TpN15, TpN17, TmpA, TpN47 separately) |
EUROLINE | IgM IgM |
16 x 01 64 x 01 |
DN 2111-1601 M DN 2111-6401 M |
||
| WESTERNBLOT |
antibodies against Treponema pallidum IgG positive control |
IgG |
50 x 05 |
CW 2111-5005 G | |||
| WESTERNBLOT |
antibodies against Treponema pallidum IgM positive control |
IgM |
50 x 05 |
CW 2111-5005 M | |||
| WESTERNBLOT | Anti-Treponema pallidum WESTERNBLOT (IgG) | Westernblot |
15 kDa, 17 kDa, 45 kDa (tmpA), 47 kDa |
IgG IgG |
16 x 01 24 x 01 |
DY 2111-1601 G DY 2111-2401 G |
|
| WESTERNBLOT | Anti-Treponema pallidum WESTERNBLOT (IgM) | Westernblot |
15 kDa, 17 kDa, 45 kDa (tmpA), 47 kDa |
IgM IgM |
16 x 01 24 x 01 |
DY 2111-1601 M DY 2111-2401 M |
|
|
* For research use only, not for in vitro diagnostic use in the sense of EU directive 98/79/EC. 1 Product manufactured by third party. Please contact your local Euroimmun representative for more information. | |||||||